Harvey Capital Management Inc. Buys New Position in Aquestive Therapeutics, Inc. (NASDAQ:AQST)

by · The Cerbat Gem

Harvey Capital Management Inc. acquired a new stake in shares of Aquestive Therapeutics, Inc. (NASDAQ:AQST – Free Report) during the third quarter, HoldingsChannel reports. The fund acquired 17,600 shares of the company’s stock, valued at approximately $88,000.

Several other institutional investors have also added to or reduced their stakes in the stock. Janney Montgomery Scott LLC boosted its stake in shares of Aquestive Therapeutics by 4.9% during the 3rd quarter. Janney Montgomery Scott LLC now owns 923,285 shares of the company’s stock valued at $4,598,000 after purchasing an additional 42,800 shares in the last quarter. Financial Advocates Investment Management lifted its holdings in Aquestive Therapeutics by 14.7% in the third quarter. Financial Advocates Investment Management now owns 39,000 shares of the company’s stock worth $194,000 after buying an additional 5,000 shares during the period. International Assets Investment Management LLC bought a new stake in Aquestive Therapeutics during the 3rd quarter valued at approximately $990,000. nVerses Capital LLC purchased a new position in shares of Aquestive Therapeutics during the 3rd quarter worth approximately $28,000. Finally, Creative Planning raised its position in shares of Aquestive Therapeutics by 39.3% in the 3rd quarter. Creative Planning now owns 92,822 shares of the company’s stock worth $462,000 after acquiring an additional 26,185 shares in the last quarter. 32.45% of the stock is currently owned by institutional investors.

Aquestive Therapeutics Stock Performance

Shares of NASDAQ:AQST traded up $0.03 during midday trading on Friday, reaching $5.52. 1,317,549 shares of the company’s stock traded hands, compared to its average volume of 1,744,926. Aquestive Therapeutics, Inc. has a one year low of $1.41 and a one year high of $6.23. The company has a market cap of $502.65 million, a price-to-earnings ratio of -15.77 and a beta of 2.85. The stock has a 50 day moving average of $4.88 and a 200 day moving average of $3.81.

Aquestive Therapeutics (NASDAQ:AQST – Get Free Report) last posted its earnings results on Tuesday, August 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.11) by $0.08. The company had revenue of $20.10 million for the quarter, compared to the consensus estimate of $12.62 million. During the same quarter in the prior year, the company posted ($0.10) EPS. Sell-side analysts predict that Aquestive Therapeutics, Inc. will post -0.48 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts recently weighed in on AQST shares. JMP Securities reaffirmed a “market outperform” rating and issued a $9.00 price target on shares of Aquestive Therapeutics in a research note on Tuesday, October 8th. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price on shares of Aquestive Therapeutics in a research report on Friday, October 25th. Finally, Leerink Partners increased their price target on shares of Aquestive Therapeutics from $12.00 to $13.00 and gave the stock an “outperform” rating in a research note on Friday, October 25th. Six analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and a consensus price target of $8.83.

Get Our Latest Research Report on AQST

Aquestive Therapeutics Profile

(Free Report)

Aquestive Therapeutics, Inc operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder.

Recommended Stories

Want to see what other hedge funds are holding AQST? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Aquestive Therapeutics, Inc. (NASDAQ:AQST – Free Report).